<?xml version="1.0" encoding="UTF-8"?>
<p>In our cohort, among those with empirical coverage for atypical pathogens, 88% were given doxycycline. The use of doxycycline as part of a combination therapy for CAP for coverage of atypical pathogens was less well evaluated, compared with macrolide or respiratory fluoroquinolones [
 <xref rid="CIT0004" ref-type="bibr">4</xref>]. In a retrospective study in San Francisco, empirical ceftriaxone and doxycycline reduced in-patient and 30-day mortality in patients hospitalized for CAP, compared with other antibiotic regimens [
 <xref rid="CIT0021" ref-type="bibr">21</xref>]. In another retrospective study in Australia, doxycycline was shown to have comparable effects on outcomes compared with macrolide, both of which were used in combination with beta-lactam therapy in patients hospitalized with CAP [
 <xref rid="CIT0022" ref-type="bibr">22</xref>].
</p>
